DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for MTT assay are 379

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_1910	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1911	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1912	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1922	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (65 %)	Approved	29315671
DrugRepV_1923	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (70 %)	Approved	29315671
DrugRepV_1924	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (62.5 %)	Approved	29315671
DrugRepV_2974	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (65 %)	Approved	25970853
DrugRepV_2975	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (71.6 %)	Approved	25970853
DrugRepV_2976	Doxycycline-Ribavirin	NA	NA	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (88.2 %)	Approved	25970853
DrugRepV_3323	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		MTT assay	Decrease (50 %)	Approved	23459490
DrugRepV_3864	Favipiravir	Antiviral	Influenza virus	Crimean-Congo hemorrhagic fever virus	Afg-09 2990	NA	MTT assay	Decrease (50 %)	Investigational	27736754
DrugRepV_3865	Favipiravir	Antiviral	Influenza virus	Ebola virus	Mayinga 1976	NA	MTT assay	Decrease (50 %)	Investigational	27736754
DrugRepV_4184	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4185	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	SL10571	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4186	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4187	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	S27	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4188	1-(4-{2-[1-cyclohexyl-2-(furan-3-yl)-1H-1,3-benzodiazol-5-yl]-1,3-oxazol-5-yl}phenyl)pyrrolidin-2-one	NA	NA	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	NA	28236746
DrugRepV_4189	Favipiravir	Antiviral	Influenza virus	Chikungunya virus	BaH306	NA	MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_4302	Carbocyclic adenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4303	Carbocyclic 3-deazaadenosine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4304	9-[trans- 2,trans - 3 - dihydroxy - 4 - (methyl) - cyclopent - 4 - enyl] - 3 - deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4305	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-adenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4306	9-[trans-2,trans-3-dihydroxy-4-hydroxymethyl-cyclopent-4-enyl]-3-deazaadenine	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4307	9-[trans-2,trans-3-dihydroxycyclopent-4-enyl]- adenine (DHCpAdo)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4308	9-[trans-2,trans-3-dihydroxycyclopent- 4-enyl]-3-deazaadenine (DHCp-c3Ado)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4309	4,5- didehydro-5-deoxy-5-fluoroadenosine (DDFA)	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4310	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved	9988190
DrugRepV_4311	Guanosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	NA	9988190
DrugRepV_4312	Adenosine Dialdehyde	NA	NA	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved, Investigational	9988190
DrugRepV_5409	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5410	Desethylamodiaquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5411	Desethylchloroquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5412	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5413	Desethylamodiaquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5414	Desethylchloroquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5415	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5416	Desethylamodiaquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5417	Desethylchloroquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5484	Chlorcyclizine	Respiratory System	Allergic rhinitis	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Approved	31850756
DrugRepV_6038	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6039	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6040	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6041	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6042	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6043	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6044	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6045	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6046	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6047	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6048	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6049	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6050	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6051	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6052	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6053	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6054	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6055	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6056	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6057	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6058	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6059	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6060	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6061	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6062	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6101	CM-10-18	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6102	IHVR11029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6103	IHVR17028	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6104	IHVR19029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6115	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/PHL/10-07		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6116	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/INDIA/09–74		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6124	Tomatidine	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6125	Tomatidine	NA	NA	Dengue virus	16007		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6126	Tomatidine	NA	NA	Dengue virus	H87		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6127	Tomatidine	NA	NA	Dengue virus	1036		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6158	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		MTT assay	Decrease (50 %)	Approved	22068705
DrugRepV_6159	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		MTT assay	Decrease (50 %)	Approved	22068705
DrugRepV_6160	5hydroxyl-6,7,3,4,5-pentamethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6161	5,3-dihydroxy-6,7,4,5-tetramethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6162	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (85 %)	NA	27490721
DrugRepV_6163	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6164	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (65 %)	NA	27490721
DrugRepV_6165	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6867	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6868	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6869	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6870	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6871	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6872	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6873	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6874	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6875	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6876	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6877	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6878	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6879	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6880	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6881	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6882	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6883	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6884	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6885	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6886	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6887	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6888	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6889	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6890	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6891	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6892	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6893	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6894	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6895	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6896	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Human immunodeficiency virus	NA		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6897	Phorbol	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6898	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6899	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6900	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6901	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6902	Phorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6903	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6904	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6905	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6906	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6907	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6908	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6909	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6910	12-O-tetradecanoyl-4γ-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6911	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6912	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6913	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6914	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6915	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6916	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6917	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6918	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6919	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6920	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6921	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6922	Ingenol	Dermatologicals	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6923	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6924	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6925	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6926	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6927	Phorbol	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6928	Phorbol-12-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6929	Phorbol-12-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6930	Phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6931	Phorbol-13-butyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6932	Pphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6933	Phorbol-13-tetradecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6934	Phorbol-12,13-diacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6935	Phorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6936	Phorbol-12,13- dihexanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6937	Phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6938	4α-phorbol-12,13-didecanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6939	12-O-tetradecanoylphorbol-13-acetate	NA	Cancer	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Phase II	25970561
DrugRepV_6940	12-O-tetradecanoyl-4?-phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6941	12-O- tiglylphorbol-13-decanoate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6942	12-O-(N-methylanthranilate) phorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6943	Phorbol-13,20-diacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6944	12,13-O,O-dinonanoylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6945	12-O-phenylacetyl-13-O-acetylphorbol-20-homovanillate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6946	Phorbol-12,13,20-triacetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6947	20-oxo-20-deoxyphorbol-12,13-dibutyrate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6948	12-O-tetradecanoyl-20-oxo-20-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6949	12-deoxyphorbol-13-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6950	13-O-isobutyryl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6951	13-O-phenylacetyl-12-deoxyphorbol-20-acetate	NA	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6952	Ingenol	Dermatologicals	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6953	Ingenol-3-mebutate	Dermatologicals	Actinic keratosis	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6954	Ingenol-3,20-dibenzoate	Dermatologicals	NA	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	NA	25970561
DrugRepV_6955	Resiniferatoxin	NA	Interstitial cystitis and urinary incontinence	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Investigational	25970561
DrugRepV_6956	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_7115	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7116	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7117	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7118	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7119	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7120	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7121	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7122	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7123	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7124	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7125	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7126	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7127	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7128	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7129	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7130	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7131	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7132	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7133	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7134	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7135	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7136	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7137	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7138	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7139	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7140	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7141	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7142	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7143	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7144	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7145	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7146	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7147	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7148	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7149	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7150	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7151	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7152	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7153	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7154	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7155	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7156	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7157	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7158	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7159	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7160	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7161	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7162	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7163	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7164	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7165	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7166	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7167	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7168	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7169	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7908	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7909	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7910	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7911	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7912	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7913	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7914	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7915	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7916	Obatoclax	Anticancer	Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7917	OSU-03012	Anticancer	Brain cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7918	Antimycin A	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7919	Brequinar	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7920	6-Azauridine	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7921	Azaribine	NA	Psoriasis	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7922	Pyrazofurin	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7923	AVN-944	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7924	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7925	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7926	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7927	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7928	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7929	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7930	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7931	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7932	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7933	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7934	Antimycin A	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7935	Brequinar	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7936	6-Azauridine	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7937	Azaribine	NA	Psoriasis	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7938	Pyrazofurin	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7939	AVN-944	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7940	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7941	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_8277	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Phase III	32488021
DrugRepV_8278	Simeprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Approved	32488021
DrugRepV_8339	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8340	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8341	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8342	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8343	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8344	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8345	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8346	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8347	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8348	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8349	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8350	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8351	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8352	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8353	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8354	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8355	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8356	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8357	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8358	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8359	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8360	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8361	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8362	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8363	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8364	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8365	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8366	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	E138K		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8367	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8368	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8369	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8370	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8371	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8372	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8373	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8374	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8375	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8376	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8377	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8378	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8379	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8380	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	L100I		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8381	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8382	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8383	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8384	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8385	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8386	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8387	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8388	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8389	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8390	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8391	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8392	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8393	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8394	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	K103N		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8395	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8396	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8397	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8398	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8399	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8400	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8401	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8402	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8403	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8404	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8405	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8406	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8407	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8408	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y181C		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8409	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8410	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8411	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8412	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8413	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8414	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8415	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8416	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8417	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8418	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8419	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8420	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8421	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8422	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	Y188L		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8423	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8424	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8425	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8426	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8427	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8428	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8429	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8430	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8431	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8432	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8433	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8434	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8435	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8436	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	F227L + V106A		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8437	((4-((3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8438	((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8439	((4-((3,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8440	4-((4-((2,3-difluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8441	((4-((3-fluoro-2-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8442	((4-((3-fluoro-3-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8443	((4-((3-fluoro-4-methyl-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8444	((4-((3-fluoro-2-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino) methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8445	((4-((3-fluoro-3-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8446	((4-((3-fluoro-4-methoxy-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8447	((4-((2-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino) benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8448	((4-((4-chloro-3-fluoro-[1,1-biphenyl]-4-yl)(hydroxyimino)methyl)pyrimidin-2-yl)amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8449	((4-((3-fluoro-2-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8450	((4-((3-fluoro-4-(trifluoromethyl)-[1,1-biphenyl]-4-yl)(hydroxylimino)methyl)pyrimidin-2-yl) amino)benzonitrile	NA	NA	Human immunodeficiency virus	RES056		MTT assay	Decrease (50 %)	NA	32334191
DrugRepV_8452	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational	30866762
DrugRepV_8453	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational	30866762
DrugRepV_8454	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational, Vet approved	30866762
DrugRepV_8455	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational, Vet approved	30866762